Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $30.42M | $30.55M | $33.46M | $26.58M |
| Net Income | $9.44M | $10.09M | $11.37M | $8.62M |
| EPS Diluted | $0.67 |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| $0.68 |
| $0.76 |
| $0.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
